Literature DB >> 31497231

lncRNA SNHG20 promotes prostate cancer migration and invasion via targeting the miR-6516-5p/SCGB2A1 axis.

Xingcheng Wu1, Yu Xiao2, Yi Zhou1, Zhien Zhou1, Weigang Yan1.   

Abstract

Accumulating evidence has demonstrated the vital roles of long noncoding RNA (lncRNA) in prostate cancer (PCa). However, the function of small nucleolar RNA host gene 20 (SNHG20) in PCa is still unclear. This study aimed to investigate the expression and biological roles of SNHG20 in PCa. SNHG20 expression in PCa tissues and cell lines was measured by quantitative real-time PCR. Gain and loss-of-function experiments were conducted to examine the biological roles of SNHG20. Bioinformatic analysis and dual luciferase activity reporter assay were conducted to establish the SNHG20/secretoglobin family 2A member 1 (SCGB2A1)/microRNA-6516-5p (miR-6516-5p) axis. SHNG20 expression was found markedly elevated in PCa tissues and cell lines. Overexpression of SNHG20 increased PCa cell proliferation and invasion but decreased cell apoptosis. However, the knockdown of SNHG20 will cause the opposite effects on PCa cell behaviors. Mechanical investigation found that SNHG20 could relive the SCGB2A1 protein expression via sponging the miR-6516-5p, acting as miRNA sponge. In conclusion, this finding suggests the SNHG20/miR-6516-5p/SCGB2A1 axis in PCa tumorigenesis, providing the novel insight for the molecular mechanism of PCa.

Entities:  

Keywords:  SCGB2A1; SNHG20; ceRNA; miR-6516-5p; prostate cancer

Year:  2019        PMID: 31497231      PMCID: PMC6731428     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  17 in total

1.  Non-coding RNA: More uses for genomic junk.

Authors:  Karen Adelman; Emily Egan
Journal:  Nature       Date:  2017-03-08       Impact factor: 49.962

Review 2.  Prevention and early detection of prostate cancer.

Authors:  Jack Cuzick; Mangesh A Thorat; Gerald Andriole; Otis W Brawley; Powel H Brown; Zoran Culig; Rosalind A Eeles; Leslie G Ford; Freddie C Hamdy; Lars Holmberg; Dragan Ilic; Timothy J Key; Carlo La Vecchia; Hans Lilja; Michael Marberger; Frank L Meyskens; Lori M Minasian; Chris Parker; Howard L Parnes; Sven Perner; Harry Rittenhouse; Jack Schalken; Hans-Peter Schmid; Bernd J Schmitz-Dräger; Fritz H Schröder; Arnulf Stenzl; Bertrand Tombal; Timothy J Wilt; Alicja Wolk
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

Review 3.  Non-coding RNA networks in cancer.

Authors:  Eleni Anastasiadou; Leni S Jacob; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2017-11-24       Impact factor: 60.716

4.  A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?

Authors:  Leonardo Salmena; Laura Poliseno; Yvonne Tay; Lev Kats; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-07-28       Impact factor: 41.582

Review 5.  Biochemical Methods To Investigate lncRNA and the Influence of lncRNA:Protein Complexes on Chromatin.

Authors:  Emily J McFadden; Amanda E Hargrove
Journal:  Biochemistry       Date:  2016-02-24       Impact factor: 3.162

6.  SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance.

Authors:  Koji Munakata; Mamoru Uemura; Ichiro Takemasa; Miyuki Ozaki; Masamitsu Konno; Junichi Nishimura; Taishi Hata; Tsunekazu Mizushima; Naotsugu Haraguchi; Shingo Noura; Masakazu Ikenaga; Shu Okamura; Mutsumi Fukunaga; Kohei Murata; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori
Journal:  Int J Oncol       Date:  2014-02-28       Impact factor: 5.650

Review 7.  Non-coding RNAs, epigenetics, and cancer: tying it all together.

Authors:  Humberto J Ferreira; Manel Esteller
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

8.  Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Authors:  J Athene Lane; Jenny L Donovan; Michael Davis; Eleanor Walsh; Daniel Dedman; Liz Down; Emma L Turner; Malcolm D Mason; Chris Metcalfe; Tim J Peters; Richard M Martin; David E Neal; Freddie C Hamdy
Journal:  Lancet Oncol       Date:  2014-08-19       Impact factor: 41.316

9.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Authors:  Benjamin A Teply; Hao Wang; Brandon Luber; Rana Sullivan; Irina Rifkind; Ashley Bruns; Avery Spitz; Morgan DeCarli; Victoria Sinibaldi; Caroline F Pratz; Changxue Lu; John L Silberstein; Jun Luo; Michael T Schweizer; Charles G Drake; Michael A Carducci; Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade
Journal:  Lancet Oncol       Date:  2017-12-14       Impact factor: 41.316

10.  Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.

Authors:  S Bellone; R Tassi; M Betti; D English; E Cocco; S Gasparrini; I Bortolomai; J D Black; P Todeschini; C Romani; A Ravaggi; E Bignotti; E Bandiera; L Zanotti; S Pecorelli; L Ardighieri; M Falchetti; C Donzelli; E R Siegel; M Azodi; D-A Silasi; E Ratner; P E Schwartz; T J Rutherford; A D Santin
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

View more
  21 in total

1.  LINC01303 promotes the proliferation and migration of laryngeal carcinoma by regulating miR-200c/TIMP2 axis.

Authors:  Dong Xiao; Xiangyan Cui; Ning Fang; Shujian Yu; Xin Wang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 2.  Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers.

Authors:  Zitong Yang; Qinchen Li; Xiangyi Zheng; Liping Xie
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

3.  Knockdown of lncRNA PVT1 inhibits prostate cancer progression in vitro and in vivo by the suppression of KIF23 through stimulating miR-15a-5p.

Authors:  Huijuan Wu; Xin Tian; Chaoyang Zhu
Journal:  Cancer Cell Int       Date:  2020-07-02       Impact factor: 5.722

4.  LncRNA DSCAM-AS1 Promotes Colon Cancer Cells Proliferation and Migration via Regulating the miR-204/SOX4 Axis.

Authors:  Canrong Lu; Tianyu Xie; Xin Guo; Di Wu; Shuo Li; Xiongguang Li; Yixun Lu; Xinxin Wang
Journal:  Cancer Manag Res       Date:  2020-06-09       Impact factor: 3.989

5.  MIR-138-5P inhibits the progression of prostate cancer by targeting FOXC1.

Authors:  Hui Huang; Ying Xiong; Zhensheng Wu; Yuhui He; Xianglin Gao; Zhangyan Zhou; Tao Wang
Journal:  Mol Genet Genomic Med       Date:  2020-02-28       Impact factor: 2.183

6.  SP1 induced long non-coding RNA LINC00958 overexpression facilitate cell proliferation, migration and invasion in lung adenocarcinoma via mediating miR-625-5p/CPSF7 axis.

Authors:  Longhai Yang; Lili Li; Zizi Zhou; Yi Liu; Jinyuan Sun; Xiaoming Zhang; Huiyu Pan; Song Liu
Journal:  Cancer Cell Int       Date:  2020-01-23       Impact factor: 5.722

7.  Identification of long non-coding RNA signatures for squamous cell carcinomas and adenocarcinomas.

Authors:  Suyan Tian; Mingbo Tang; Jialin Li; Chi Wang; Wei Liu
Journal:  Aging (Albany NY)       Date:  2020-12-09       Impact factor: 5.682

8.  Inhibition of Long Noncoding RNA SNHG20 Improves Angiotensin II-Induced Cardiac Fibrosis and Hypertrophy by Regulating the MicroRNA 335/Galectin-3 Axis.

Authors:  Mingyang Li; Chunli Qi; Renxing Song; Chunming Xiong; Xiao Zhong; Ziguang Song; Zhongping Ning; Xiang Song
Journal:  Mol Cell Biol       Date:  2021-08-24       Impact factor: 4.272

9.  lncRNA UCA1 Functions as a ceRNA to Promote Prostate Cancer Progression via Sponging miR143.

Authors:  Yanlan Yu; Fengbin Gao; Qian He; Gonghui Li; Guoqing Ding
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-27       Impact factor: 8.886

10.  lncRNA RASSF8‑AS1 suppresses the progression of laryngeal squamous cell carcinoma via targeting the miR‑664b‑3p/TLE1 axis.

Authors:  Tao Liu; Wenxia Meng; Huan Cao; Weiwei Chi; Lei Zhao; Weina Cui; Huan Yin; Baoshan Wang
Journal:  Oncol Rep       Date:  2020-09-16       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.